Although renal denervation didn’t go down so well for the management of refractory hypertension, that doesn’t mean the problem has gone away. This new randomised controlled trial is about trying something a little different – and the early results look promising. Check it out at the Lancet, here.
For acute blood pressure control in pregnancy, different hospitals often have different guidelines. Hydralazine used to be all the rage but fell out of favour after a concerning safety profile was highlighted. Intravenous labetalol is commonly used, but many also consider nifedipine first line. This double blind randomised controlled trial from India aims to settle the issue.